Carboplatin or cisplatin

DRUG11 trials

Sponsors

Samsung Medical Center, Peking Union Medical College Hospital, University of Illinois at Chicago, Hirva Mamdani, The University of Hong Kong

Conditions

Esophageal Squamous Cell CarcinomaExtensive Stage Small Cell Lung CancerExtensive-stage Small Cell Lung CancerExtensive-stage Small-cell Lung CancerLimited Stage Small-Cell Lung CancerMetastatic Squamous Non-Small Cell Lung CarcinomaNon-Small Cell Lung CancerNon-small Cell Lung Cancer

Phase 2

Neoadjuvant Pembrolizumab Plus Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

CompletedNCT05302011

Peking Union Medical College HospitalEsophageal Squamous Cell Carcinoma

Start: 2020-06-01End: 2023-06-30Updated: 2023-10-10

A Pilot Phase II Study of Maintenance Cabozantinib Plus Pembrolizumab for Patients With Metastatic Squamous Non-Small Cell Lung Cancer (sqNSCLC)

RecruitingNCT05613413

University of Illinois at ChicagoMetastatic Squamous Non-Small Cell Lung Carcinoma

Start: 2022-12-28End: 2028-09-30Target: 36Updated: 2026-01-08

MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer

RecruitingNCT05903092

Hirva MamdaniExtensive Stage Small Cell Lung Cancer, Limited Stage Small-Cell Lung Cancer, SCLC +1

Start: 2023-09-26End: 2030-10-31Target: 84Updated: 2026-04-29

Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC

RecruitingNCT06536868

Second Hospital of Shanxi Medical UniversityExtensive-stage Small-cell Lung Cancer

Start: 2024-08-01End: 2026-12-31Target: 40Updated: 2026-04-24

Phase II Clinical Study of JS207 (PD-1/VEGF Bispecific Antibody) Combination Therapies in Patients With Driver Gene-Positive, Advanced Non-Small Cell Lung Cancer After Failure of TKI Therapy

RecruitingNCT06868836

Shanghai Junshi Bioscience Co., Ltd.Non-squamous Non-small Cell Lung Cancer

Start: 2025-03-30End: 2028-04-04Target: 78Updated: 2026-05-18

A Study of Benmelstobart, Anlotinib, Chemotherapy and Thoracic Radiotherapy for People With Extensive-stage Small Cell Lung Cancer

Not yet recruitingNCT07538271

Yayi HeSCLC, Extensive Stage

Start: 2026-04-20End: 2029-03-31Target: 33Updated: 2026-04-20

Phase 3

Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC

Samsung Medical CenterNon-small Cell Lung Cancer

Start: 2019-08-27End: 2024-03-11Updated: 2023-04-03

A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

RecruitingNCT06711900

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Non-Small Cell Lung Cancer

Start: 2024-10-30End: 2028-12-01Target: 432Updated: 2026-02-05

Phase 4

Preoperative Neoadjuvant Immunotherapy Combined With Chemotherapy for Stage Ⅲ Unresectable Non-small Cell Lung Cancer

RecruitingNCT06357598

The Affiliated Hospital of Qingdao UniversityNon-small-cell Lung Cancer (NSCLC)

Start: 2024-01-18End: 2025-12-31Target: 30Updated: 2024-04-10

Benmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer

Not yet recruitingNCT06931145

Peking Union Medical College HospitalExtensive-stage Small Cell Lung Cancer

Start: 2025-04-15End: 2027-12-31Target: 50Updated: 2025-04-23

Unknown Phase

Secondary Interval Cytoreductive Surgery in Platinum-sensitive Recurrent Epithelial Ovarian Cancer

RecruitingNCT06292286

The University of Hong KongRecurrent Ovarian Carcinoma

Start: 2023-11-01End: 2026-12-31Target: 18Updated: 2025-06-11

Related Papers

Artificial intelligence-powered spatial analysis of tumor microenvironment in patients with non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitor.

2025-10-31

Sacituzumab tirumotecan (sac-TMT) in combination with tagitanlimab (anti-PD-L1) in first-line (1L) advanced non-small-cell lung cancer (NSCLC): Non-squamous cohort from the phase II OptiTROP-Lung01 study.

Journal of Clinical Oncology2025-05-281 citations

Neoadjuvant immunochemotherapy for locally advanced esophageal squamous cell carcinoma: Pooled results analysis from two prospective single-arm phase 2 trials.

Journal of Clinical Oncology2025-05-28

A phase II trial of monalizumab in combination with durvalumab (MEDI4736) plus platinum-based chemotherapy for first-line treatment of extensive stage small cell lung cancer (MOZART): Hoosier Cancer Research Network LUN21-530 study.

Journal of Clinical Oncology2024-06-011 citations

A prospective phase 2 single-arm study to evaluate the efficacy and safety of neoadjuvant pembrolizumab plus chemotherapy in patients with locally advanced esophageal squamous cell carcinoma (Keypoint-1).

Journal of Clinical Oncology2024-06-01

700 A phase II trial of MOnaliZumab plus durvAlumab plus platinum-based chemotheRapy for first-line treatment of extensive stage small cell lung cancer (MOZART): A Hoosier Cancer Research Network study

Regular and Young Investigator Award Abstracts2023-10-311 citations

LUNG-IST-127: A pilot phase II study of maintenance cabozantinib plus pembrolizumab for patients with metastatic squamous non-small cell lung cancer (sqNSCLC) with disease control following induction therapy.

Journal of Clinical Oncology2023-06-01

A phase III, open-label, randomized study of atezolizumab in combination with carboplatin + paclitaxel + bevacizumab compared with pemetrexed + cisplatin or carboplatin with stage IV non-squamous non-small cell lung cancer (NSCLC) with activating EGFR mutation or ALK translocation (ATLAS Trial).

Journal of Clinical Oncology2020-05-202 citations